Immune Response News and Research

RSS

SARS-CoV-2 infection can produce self-attacking autoantibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild symptoms or no symptoms at all, according to Cedars-Sinai investigators.

30 Dec 2021

Booster doses of mRNA vaccines improve humoral immunogenicity in patients with inflammatory bowel disease

Researchers evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with inflammatory bowel disease.

30 Dec 2021

An integrated computational methodology for COVID drug prioritization

Researchers recently published a study in the journal Briefings in Bioinformatics wherein they integrated multiple bioinformatics and cheminformatics-based methods to prioritize drugs for the treatment of COVID-19.

29 Dec 2021

Study sheds light on how the immune system behaves during pregnancy

Pregnancy is a challenge for the mother's immune system from the outset. Half of the genes in the fetus are foreign to her body.

29 Dec 2021

SARS-CoV-2 infection induces robust and cross-reactive immune responses in children

Researchers compare the convalescent humoral and cellular immune responses between children and adults infected with SARS-CoV-2.

28 Dec 2021

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

A new preprint* research paper under consideration at Nature Portfolio Journal assesses the susceptibility of the Omicron variant to neutralizing antibody response after booster immunization.

28 Dec 2021

SARS-CoV-2 Alpha variant mutated to evade the immune system

The SARS-CoV-2 Alpha (B.1.1.7) variant mutated to evade our 'innate immune system', helping establish it as the world's first 'Variant of Concern', finds a new study led by researchers at UCL and the Quantitative Biosciences Institute, University of California San Francisco.

24 Dec 2021

Study helps explain why mRNA vaccines have been successful at preventing severe COVID-19

Washington University in St. Louis student Julian McCall receives a dose of Pfizer's mRNA-based COVID-19 vaccine.

24 Dec 2021

Study hints subtle differences in the quality of immune response based on COVID-19 severity

Infection-fighting B cells retain better memory of the coronavirus spike protein in University Hospital patients who recover from less-severe cases of COVID-19 than in those recovering from severe COVID-19, a new study suggests.

24 Dec 2021

Inhaled CBD shrinks glioblastoma’s size in an animal model

Inhaled CBD shrinks the size of the highly aggressive, lethal brain tumor glioblastoma in an animal model by reducing the essential support of its microenvironment, researchers report.

24 Dec 2021

Alpha variant of SARS-CoV-2 evolved mutations to evade the immune system

The Alpha variant of SARS-CoV-2 - the first "variant of concern" - evolved mutations that allowed it to more efficiently suppress the immune system's early response to infection, according to a new study led by scientists at the University of California, San Francisco's Quantitative Biosciences Institute and University College London.

24 Dec 2021

Pfizer-BioNTech booster shot may offer better immunity than a two-dose regimen

A new study suggests that the immune response against severe acute respiratory syndrome coronavirus 2 is greater with a three-dose regimen than a two-dose regimen.

24 Dec 2021

Children with pre-existing immunity to common cold demonstrate better protection against COVID-19

New data shows that, compared to adults, children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) preferentially activate pre-existing acquired immunity to prevalent common cold coronaviruses that cross-react with SARS-CoV-2 and protect them from severe disease.

24 Dec 2021

Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

Researchers find that vaccine-mediated protection against SARS-CoV-2 is significantly reduced against the Omicron variant.

23 Dec 2021

Blocking function of a blood-clotting protein may help prevent or treat periodontal disease

Blocking function of a blood-clotting protein prevented bone loss from periodontal (gum) disease in mice, according to research led by scientists at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health.

23 Dec 2021

Fiber-rich diet may help some melanoma patients to respond to immunotherapy

A diet rich in fiber may help some people being treated for melanoma respond to immunotherapy treatment by influencing the gut microbiome, according to a new study led by researchers at the Center for Cancer Research at the National Cancer Institute, part of the National Institutes of Health, and the University of Texas MD Anderson Cancer Center.

23 Dec 2021

Exploring why children have milder COVID-19 infections compared to adults

A new study has revealed that an activated pre-exposure innate interferon response in airways together with significantly reduced systemic interferon-stimulated populations are associated with relatively milder severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children.

23 Dec 2021

Exploring immunity and severe disease caused by the SARS-CoV-2 Omicron variant

A new study describes the findings of a seroprevalence survey intended to establish the infection rates and the incidence of severe COVID-19 through December 15, 2021, in Gauteng, a crowded province that compresses a quarter of the country’s people into less than 2% of its area.

23 Dec 2021

Study reports that children develop sustained cross-reactive adaptive immunity against coronaviruses

A new study shows that both antibody and cellular arms of the adaptive immune response against SARS-CoV-2 are displayed strong, sustained, and cross-reactive against other coronaviruses, in young children than the immune responses in adults.

23 Dec 2021

T-cell response to Omicron after an mRNA COVID vaccine booster

In a recent prospective observational study posted to the medRxiv* preprint server, researchers determined Omicron variant-associated T cell responses before and after a third dose of messenger ribonucleic acid (mRNA) vaccination against coronavirus disease (COVID-19) in anti-CD20-treated multiple sclerosis (MS) patients.

22 Dec 2021